File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3960/jslrt.51.21
- Scopus: eid_2-s2.0-80054017714
- PMID: 21628857
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Title | The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. |
---|---|
Authors | |
Issue Date | 2011 |
Citation | Journal Of Clinical And Experimental Hematopathology : Jceh, 2011, v. 51 n. 1, p. 21-28 How to Cite? |
Abstract | Natural killer (NK) cell lymphomas are rare malignancies. They are classified as extranodal NK/T-cell lymphoma, nasal type, and aggressive NK cell leukemia. NK cell neoplasms are prevalent in Asian and South American populations, but are extremely rare in the West. They can be classified clinically into nasal, non-nasal, and aggressive lymphoma/leukemia subtypes. For nasal NK cell lymphomas, combined chemotherapy and radiotherapy are indicated for stage I/II disease. Chemotherapy is the main treatment for stage III/IV nasal NK cell lymphomas, as well as the non-nasal and aggressive subtypes. Regimens containing drugs not affected by the P-glycoprotein, particularly in combination with L-asparaginase, have resulted in much improvement in treatment outcome for high-risk, refractory or relapsed patients. Autologous or allogeneic hematopoietic stem cell transplantation should be considered for selected patients. Epstein-Barr virus DNA load as a surrogate marker for prognostication, and clinical stratification of patients should be incorporated in clinical management algorithms. |
Persistent Identifier | http://hdl.handle.net/10722/163409 |
ISSN | 2023 Impact Factor: 0.9 2023 SCImago Journal Rankings: 0.356 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | YokLam, K | en_US |
dc.date.accessioned | 2012-09-05T05:30:59Z | - |
dc.date.available | 2012-09-05T05:30:59Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Journal Of Clinical And Experimental Hematopathology : Jceh, 2011, v. 51 n. 1, p. 21-28 | en_US |
dc.identifier.issn | 1880-9952 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163409 | - |
dc.description.abstract | Natural killer (NK) cell lymphomas are rare malignancies. They are classified as extranodal NK/T-cell lymphoma, nasal type, and aggressive NK cell leukemia. NK cell neoplasms are prevalent in Asian and South American populations, but are extremely rare in the West. They can be classified clinically into nasal, non-nasal, and aggressive lymphoma/leukemia subtypes. For nasal NK cell lymphomas, combined chemotherapy and radiotherapy are indicated for stage I/II disease. Chemotherapy is the main treatment for stage III/IV nasal NK cell lymphomas, as well as the non-nasal and aggressive subtypes. Regimens containing drugs not affected by the P-glycoprotein, particularly in combination with L-asparaginase, have resulted in much improvement in treatment outcome for high-risk, refractory or relapsed patients. Autologous or allogeneic hematopoietic stem cell transplantation should be considered for selected patients. Epstein-Barr virus DNA load as a surrogate marker for prognostication, and clinical stratification of patients should be incorporated in clinical management algorithms. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Journal of clinical and experimental hematopathology : JCEH | en_US |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use | en_US |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Killer Cells, Natural - Pathology | en_US |
dc.subject.mesh | Leukemia - Pathology - Therapy | en_US |
dc.subject.mesh | Lymphoma, Extranodal Nk-T-Cell - Pathology - Therapy | en_US |
dc.title | The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. | en_US |
dc.type | Article | en_US |
dc.identifier.email | YokLam, K:ylkwong@hku.hk | en_US |
dc.identifier.authority | YokLam, K=rp00358 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.3960/jslrt.51.21 | en_US |
dc.identifier.pmid | 21628857 | - |
dc.identifier.scopus | eid_2-s2.0-80054017714 | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 21 | en_US |
dc.identifier.epage | 28 | en_US |
dc.identifier.scopusauthorid | YokLam, K=7102818954 | en_US |
dc.identifier.issnl | 1346-4280 | - |